Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
.png "Maureen Dubreuil, MD, MSc photo")
Maureen Dubreuil, MD, MSc
Boston University School of Medicine
Milton, MA, United States
Disclosure(s): Amgen: Consultant (Ongoing); Pfizer: educational/research grants; paid to Boston University School of Medicine (Ongoing); UCB Pharma: Consultant (Ongoing)
Lianne Gensler, MD
Professor of Medicine
University of California San Francisco
San Francisco, CA, United States
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Gilead: Advisor or Review Panel Member (Terminated); Janssen: Advisor or Review Panel Member (Terminated); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Terminated), Consultant (Terminated), Grant/Research Support (Terminated); UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing)
This session will examine guidelines and current evidence regarding ankylosing spondylitis (AS) management and outcomes. Speakers will present data to highlight the evolution of treatment strategies. The session will focus on evidence for state-of-the-art treatments in AS, including assessing whether treat to target is a paradigm that fits AS. Speakers will assess the current state of evidence and determine what further studies will be useful to support or refute use of treat to target in AS.
Speaker: Alexis Ogdie, MD – University of Pennsylvania
